Hormonal treatment of patients with benign prostatic hyperplasia: Pros and cons

Current Urology Reports

Volumn 2, Issue 4, 2001, Pages 285-291

  Wise, Gilbert J ^a   Ostad, Edward ^a  

^a MAIMONIDES MEDICAL CENTER   (United States)

Author keywords

Benign Prostatic Hyperplasia; Finasteride; International Prostate Symptom Score; Lower Urinary Tract Symptom; Prostate Volume

Indexed keywords

ENZYME INHIBITOR; FINASTERIDE;

HUMAN; MALE; PROSTATE HYPERTROPHY; REVIEW;

ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; PROSTATIC HYPERPLASIA;

EID: 0035427976     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-001-0065-1     Document Type: Article

References (36)

1. Altman LK: Common drug for prostrate is ineffective, study finds. The New York Times, August 22, 1996.
2. Lepor H, Williford WO, Barry MJ, et al.: The efficacy of terazosin, finasteride, or both in benign prostatic hyper-plasia. N Engl J Med 1996, 335:533–539. This study brought into focus the role, if any, that finasteride has in the treatment of BPH. DOI: 10.1056/NEJM199608223350801
3. Schroder FH: Endocrine management of prostatic hyperplasia. In Non-Surgical Treatment of BPH. Edited by Fitzpatrick JM. Edinburgh: Churchill Livingstone; 1992.
4. Huggins C, Stevens RA: The effect of castration on benign hypertrophy of the prostate in man. J Urol 1940, 43:705–714. This study provided the basis for clinical use of hormones in the treatment of prostate disease.
5. Huggins C, Webster WO: Duality of human prostate in response to estrogen. J Urol 1948, 59:258–266.
6. Walsh PC, Wilson JD: The induction of prostatic hypertrophy in the dog with androstanediol. J Clin Invest 1976, 57:1093–1097. DOI: 10.1172/JCI108353
7. Peters CA, Walsh PC: The effect of nafarelin acetate, a luteinizing-hormone-releasing hormone agonist on benign prostatic hyperplasia. N Engl J Med 1987, 317:599–604. This paper demonstrated that medical therapy could induce a reduction in the size of BPH. DOI: 10.1056/NEJM198709033171004
8. Lee C, Kozlowski JM, Grayhack JT: Etiology of benign prostatic hyperplasia. Urol Clin North Am 1995, 22:237–246.
9. Culig Z, Hobisch A, Cronauer MV, et al.: Regulation of prostatic growth and function by peptide growth factors. The Prostate 1996, 28:392–405. DOI: 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C
10. Steiner MS: Role of peptide growth factors in the prostate: a review. Urology 1993, 42:99–110. DOI: 10.1016/0090-4295(93)90352-B
11. Gann PH, Klein KG, Chatterton RT, et al.: Growth factors in expressed prostatic fluid from men with prostate cancer, BPH, and clinically normal prostates. The Prostate 1999, 40:248–255. DOI: 10.1002/(SICI)1097-0045(19990901)40:4<248::AID-PROS6>3.0.CO;2-M
12. Gnanapragasam VJ, Robson CN, Leung HY, Neal DE: Androgen receptor signaling in the prostate. Br J Urol 2000, 86:1001–1013. An excellent review of the molecular biology of androgen interaction and prostate growth.
13. Desgrandchamps F: Clinical relevance of growth factor antagonists in the treatment of benign prostatic hyperplasia. Eur Urol 1997, 32(suppl):28–31.
14. Vaughan ED Jr, Lepor H: Medical management of BPH. American Urological Update Series. Part 1. 1996,15:18–23. This AUA series provides an in-depth review of the role of hormones in the treatment of BPH. Part 2 provides a similar review for the alpha blockers.
15. Gormley GJ, Stoner E, Rittmaster RS, et al.: Effect of finasteride (MK 906) a 5a-reductase inhibitor on circulating androgens in male volunteers. J Clin Endocrinol Metab 1990, 70:1136. DOI: 10.1210/jcem-70-4-1136
16. The MK906 (finasteride) Study Group: A one year experience in the treatment of benign prostatic hyperplasia with finasteride. J Androl 1991,12:372.
17. Gornley GJ, Stoner E, Bruskewitz RC, et al.: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992, 327:1185. DOI: 10.1056/NEJM199210223271701
18. Stoner E (Members Of The Finasteride Study Group): Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology 1994, 43:284–293. This early study added impetus to the role of finasteride in the treatment of BPH. DOI: 10.1016/0090-4295(94)90068-X
19. Gormley GJ, Stoner E, Bruskewitz RC, et al.: The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 1992, 327:1185–1191. DOI: 10.1056/NEJM199210223271701
20. Andersen JT, Ekman P, Wolf H, et al.: Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. Urology 1995, 46:631–637. DOI: 10.1016/S0090-4295(99)80291-X
21. Tammela TLJ, Kontturi M: Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia. J Urol 1996, 154:1466–1469. DOI: 10.1016/S0022-5347(01)66894-0
22. Nickel JC, Fradet Y, Boake RC, et al.: Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT Study). Can Med Assoc J 1996, 155:1251–1259. A long-term study that documented the long (8-month) period for maximum effect for finasteride therapy. The effect on sexual function was evident.
23. Andersen JT, Nickel JC, Marshall VR, et al.: Finasteride signifi-cantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997, 49:839–845. This study demonstrated a potential benefit of finasteride. DOI: 10.1016/S0090-4295(97)00185-4
24. Savage SJ, Spungen AM, Galea G, et al.: Combination medical therapy for symptomatic benign prostatic hyperplasia. Can J Urol 1998, 5:578–584.
25. McConnell JD, Bruskewitz R, Walsh P, et al.: The effect on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. N Engl J Med 1998, 338:557–563. This paper provides a review of large number of patients (more than 3000 men) who were followed for over 4 years. The high drop-out rate for finasteride group (34%) and placebo group (42%) reiterates the problems associated with long-term medical therapy. DOI: 10.1056/NEJM199802263380901
26. Schafer WLJ, Tammela D, Barret M, et al.: Continued improvement in pressure-flow parameters in men receiving finasteride for 2 years. Urology 1999, 54:278–283. This paper indicates that pressure flow changes were greater in larger responses. This supports clinical observations that the larger prostate (more than 50 g) is the better candidate for finasteride. DOI: 10.1016/S0090-4295(99)00130-2
27. Miller MI, Puchner PJ: Effects of finasteride on hematuria associated with benign prostatic hyperplasia: long term follow up. Urology 1998 51: 237–240. A common but devastating problem in older men with large prostates is recurrent bleeding. Finasteride has an important role in management of this problem. DOI: 10.1016/S0090-4295(97)00614-6
28. Foley SJ, Solomon LZ, Wedderburn AW, et al.: A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and effect of finasteride. J Urol 2000, 163:496–498. DOI: 10.1016/S0022-5347(05)67910-4
29. Rhodes PR, Krogh RH, Bruskewitz RC: Impact of drug therapy on benign prostatic hyperplasia-specific quality of life. Urology 2000, 53:1090–1099. DOI: 10.1016/S0090-4295(99)00041-2
30. Speakman MJ: Who should be treated and how? Evidence-based medicine in symptomatic BPH. Eur Urol 1999, 36(suppl):40–51. This paper points out the advantage of rapid onset effect of the alpha blockers in contrast to the delayed effect of finasteride. DOI: 10.1159/000052348
31. Tenover JL, Pagano GA, Morton AS, et al.: Efficacy and tolerability of finasteride in symptomatic benign prostatic hyperplasia: a primary care study. Clin Ther 1997, 19:243–258. DOI: 10.1016/S0149-2918(97)80113-0
32. Clifford GM, Logie J, Farmer RDT: How do symptoms indicative of BPH progress in real life practice? The UK experience. Eur Urol 2000, 38(suppl):48–53. The natural history of BPH indicates a continued growth as the patient ages. Both patient and urologist should continue to monitor prostate size and potential changes in obstructive uropathy. DOI: 10.1159/000052401
33. Lowe FC, McDaniel RL, Chmiel JJ, Hillman AL: Economic modeling to assess the costs of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyper-plasia. Urology 1995, 46:477–483. DOI: 10.1016/S0090-4295(99)80258-1
34. Bartsch G, Rittmaster RS, Klocker H: Dihydrotestosterone and the concept of 5a reductase inhibition in human benign prostatic hyperplasia. Eur Urol 2000, 37:367–380. DOI: 10.1159/000020181
35. Koivisto P, Schleutker J, Helin H, et al.: Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Clin Can Res 1999, 5:3578–3582. These observations are most disconcerting. Another reason to closely monitor patients for changes in PSA and DRE.
36. Walsh PC: Treatment of benign prostatic hyperplasia. N Engl J Med 1996, 335:586–587. This editorial points out that BPH has multifactorial causes that require different treatment modalities. DOI: 10.1056/NEJM199608223350809